Fitch downgrades Bristol-Myers Squibb's (BMY -1.4%) long-term debt to A from A+, with a negative...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Fitch downgrades Bristol-Myers Squibb's (BMY -1.4%) long-term debt to A from A+, with a negative outlook. Fitch cites BMY's purchase of Amylin and its aggressive share buybacks, as well as the the patent cliff the company's going through, as reasons for the downgrade.